ALB and neoplasm: WTX-330 is a systemically administered, selectively activated IL-12 prodrug consisting of an HSA to extend its half-life and wild-type IL-12 masked with a high-affinity anti-IL-12 scFv that are connected via tumor protease-sensitive linkers (140, 141).